Amended IN Assembly June 17, 2024 Amended IN Assembly June 10, 2024 Amended IN Senate March 18, 2024 CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION Senate Bill No. 1428Introduced by Senator AtkinsFebruary 16, 2024An act to add Section Sections 123467.4 and 127698 to the Health and Safety Code, relating to reproductive health.LEGISLATIVE COUNSEL'S DIGESTSB 1428, as amended, Atkins. Reproductive health: mifepristone. mifepristone and other medication.Under the California Constitution, the state is prohibited from denying or interfering with an individuals reproductive freedom in their most intimate decisions, including their fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.Under the act, a person is not subject to liability or penalty based on their actions or omissions with respect to their pregnancy or pregnancy outcome. Under the act, a person who aids or assists a pregnant person in exercising their rights under the act is not subject to liability or penalty based solely on their aid- or assistance-related actions, as specified.Under the bill, a person, in exercising their individual rights under the above-described constitutional provision and the Reproductive Privacy Act, would not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion. Under the bill, a person who aids or assists a pregnant person in exercising their rights under those provisions would not be subject to liability or penalty or deprivation of rights based solely on their actions to aid or assist a pregnant person in accessing any of those drugs. The bill would declare those actions as being lawful under the laws of California.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships to, among other things, address shortages in the market for generic prescription drugs and increase patient access to affordable drugs. The act also requires CHHSA to enter into partnerships resulting in the production, procurement, or distribution of generic prescription drugs.Mifepristone, a drug used for medication abortion, received approval by the United States Food and Drug Administration (FDA) in 2000. Under pending litigation in federal courts, the matter of maintaining or restricting access to mifepristone is being reviewed, including with regard to the FDA approval status of mifepristone and the authorized timeframe and methodologies for accessing the drug.This bill would state the intent of the Legislature to protect reproductive health access upon a decision in the above-described pending litigation or other change under federal law. access. The bill would authorize CHHSA or its departments to enter into partnerships resulting in the production, procurement, or distribution of mifepristone.In the event of a change in the approval status of mifepristone by the FDA, or a change in conditions for use or in the accessibility of mifepristone, the bill would authorize CHHSA or its departments to develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. The Legislature finds and declares all of the following:(a) It is the longstanding public policy of this state to promote access to reproductive health care, including abortion care, without unnecessary burdens or restrictions on patients or providers. Every pregnant individual has the fundamental right to choose to have an abortion, a right that is secured by the California Constitution.(b) Recent litigation has raised uncertainty about the continued availability nationwide of mifepristone, a drug that has been clinically proven to be part of a safe and effective means of providing medication abortion.(c) The continued attacks on reproductive freedom across the country require immediate action to protect the right to abortion access, including access to medication abortion, in California.(d) It is the intent of the Legislature to ensure continued access in California to critical abortion medication that has been proven safe and effective for two decades for individuals seeking abortion care.SEC. 2. Section 123467.4 is added to the Health and Safety Code, to read:123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.SECTION 1.SEC. 3. Section 127698 is added to the Health and Safety Code, to read:127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
Amended IN Assembly June 17, 2024 Amended IN Assembly June 10, 2024 Amended IN Senate March 18, 2024 CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION Senate Bill No. 1428Introduced by Senator AtkinsFebruary 16, 2024An act to add Section Sections 123467.4 and 127698 to the Health and Safety Code, relating to reproductive health.LEGISLATIVE COUNSEL'S DIGESTSB 1428, as amended, Atkins. Reproductive health: mifepristone. mifepristone and other medication.Under the California Constitution, the state is prohibited from denying or interfering with an individuals reproductive freedom in their most intimate decisions, including their fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.Under the act, a person is not subject to liability or penalty based on their actions or omissions with respect to their pregnancy or pregnancy outcome. Under the act, a person who aids or assists a pregnant person in exercising their rights under the act is not subject to liability or penalty based solely on their aid- or assistance-related actions, as specified.Under the bill, a person, in exercising their individual rights under the above-described constitutional provision and the Reproductive Privacy Act, would not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion. Under the bill, a person who aids or assists a pregnant person in exercising their rights under those provisions would not be subject to liability or penalty or deprivation of rights based solely on their actions to aid or assist a pregnant person in accessing any of those drugs. The bill would declare those actions as being lawful under the laws of California.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships to, among other things, address shortages in the market for generic prescription drugs and increase patient access to affordable drugs. The act also requires CHHSA to enter into partnerships resulting in the production, procurement, or distribution of generic prescription drugs.Mifepristone, a drug used for medication abortion, received approval by the United States Food and Drug Administration (FDA) in 2000. Under pending litigation in federal courts, the matter of maintaining or restricting access to mifepristone is being reviewed, including with regard to the FDA approval status of mifepristone and the authorized timeframe and methodologies for accessing the drug.This bill would state the intent of the Legislature to protect reproductive health access upon a decision in the above-described pending litigation or other change under federal law. access. The bill would authorize CHHSA or its departments to enter into partnerships resulting in the production, procurement, or distribution of mifepristone.In the event of a change in the approval status of mifepristone by the FDA, or a change in conditions for use or in the accessibility of mifepristone, the bill would authorize CHHSA or its departments to develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
Amended IN Assembly June 17, 2024 Amended IN Assembly June 10, 2024 Amended IN Senate March 18, 2024
Amended IN Assembly June 17, 2024
Amended IN Assembly June 10, 2024
Amended IN Senate March 18, 2024
CALIFORNIA LEGISLATURE 20232024 REGULAR SESSION
Senate Bill
No. 1428
Introduced by Senator AtkinsFebruary 16, 2024
Introduced by Senator Atkins
February 16, 2024
An act to add Section Sections 123467.4 and 127698 to the Health and Safety Code, relating to reproductive health.
LEGISLATIVE COUNSEL'S DIGEST
## LEGISLATIVE COUNSEL'S DIGEST
SB 1428, as amended, Atkins. Reproductive health: mifepristone. mifepristone and other medication.
Under the California Constitution, the state is prohibited from denying or interfering with an individuals reproductive freedom in their most intimate decisions, including their fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.Under the act, a person is not subject to liability or penalty based on their actions or omissions with respect to their pregnancy or pregnancy outcome. Under the act, a person who aids or assists a pregnant person in exercising their rights under the act is not subject to liability or penalty based solely on their aid- or assistance-related actions, as specified.Under the bill, a person, in exercising their individual rights under the above-described constitutional provision and the Reproductive Privacy Act, would not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion. Under the bill, a person who aids or assists a pregnant person in exercising their rights under those provisions would not be subject to liability or penalty or deprivation of rights based solely on their actions to aid or assist a pregnant person in accessing any of those drugs. The bill would declare those actions as being lawful under the laws of California.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships to, among other things, address shortages in the market for generic prescription drugs and increase patient access to affordable drugs. The act also requires CHHSA to enter into partnerships resulting in the production, procurement, or distribution of generic prescription drugs.Mifepristone, a drug used for medication abortion, received approval by the United States Food and Drug Administration (FDA) in 2000. Under pending litigation in federal courts, the matter of maintaining or restricting access to mifepristone is being reviewed, including with regard to the FDA approval status of mifepristone and the authorized timeframe and methodologies for accessing the drug.This bill would state the intent of the Legislature to protect reproductive health access upon a decision in the above-described pending litigation or other change under federal law. access. The bill would authorize CHHSA or its departments to enter into partnerships resulting in the production, procurement, or distribution of mifepristone.In the event of a change in the approval status of mifepristone by the FDA, or a change in conditions for use or in the accessibility of mifepristone, the bill would authorize CHHSA or its departments to develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
Under the California Constitution, the state is prohibited from denying or interfering with an individuals reproductive freedom in their most intimate decisions, including their fundamental right to choose to have an abortion. Existing law, the Reproductive Privacy Act, prohibits the state from denying or interfering with a pregnant persons right to choose or obtain an abortion prior to viability of the fetus, or when the abortion is necessary to protect the life or health of the pregnant person.
Under the act, a person is not subject to liability or penalty based on their actions or omissions with respect to their pregnancy or pregnancy outcome. Under the act, a person who aids or assists a pregnant person in exercising their rights under the act is not subject to liability or penalty based solely on their aid- or assistance-related actions, as specified.
Under the bill, a person, in exercising their individual rights under the above-described constitutional provision and the Reproductive Privacy Act, would not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion. Under the bill, a person who aids or assists a pregnant person in exercising their rights under those provisions would not be subject to liability or penalty or deprivation of rights based solely on their actions to aid or assist a pregnant person in accessing any of those drugs. The bill would declare those actions as being lawful under the laws of California.
Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships to, among other things, address shortages in the market for generic prescription drugs and increase patient access to affordable drugs. The act also requires CHHSA to enter into partnerships resulting in the production, procurement, or distribution of generic prescription drugs.
Mifepristone, a drug used for medication abortion, received approval by the United States Food and Drug Administration (FDA) in 2000. Under pending litigation in federal courts, the matter of maintaining or restricting access to mifepristone is being reviewed, including with regard to the FDA approval status of mifepristone and the authorized timeframe and methodologies for accessing the drug.
This bill would state the intent of the Legislature to protect reproductive health access upon a decision in the above-described pending litigation or other change under federal law. access. The bill would authorize CHHSA or its departments to enter into partnerships resulting in the production, procurement, or distribution of mifepristone.
In the event of a change in the approval status of mifepristone by the FDA, or a change in conditions for use or in the accessibility of mifepristone, the bill would authorize CHHSA or its departments to develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
## Digest Key
## Bill Text
The people of the State of California do enact as follows:SECTION 1. The Legislature finds and declares all of the following:(a) It is the longstanding public policy of this state to promote access to reproductive health care, including abortion care, without unnecessary burdens or restrictions on patients or providers. Every pregnant individual has the fundamental right to choose to have an abortion, a right that is secured by the California Constitution.(b) Recent litigation has raised uncertainty about the continued availability nationwide of mifepristone, a drug that has been clinically proven to be part of a safe and effective means of providing medication abortion.(c) The continued attacks on reproductive freedom across the country require immediate action to protect the right to abortion access, including access to medication abortion, in California.(d) It is the intent of the Legislature to ensure continued access in California to critical abortion medication that has been proven safe and effective for two decades for individuals seeking abortion care.SEC. 2. Section 123467.4 is added to the Health and Safety Code, to read:123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.SECTION 1.SEC. 3. Section 127698 is added to the Health and Safety Code, to read:127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
The people of the State of California do enact as follows:
## The people of the State of California do enact as follows:
SECTION 1. The Legislature finds and declares all of the following:(a) It is the longstanding public policy of this state to promote access to reproductive health care, including abortion care, without unnecessary burdens or restrictions on patients or providers. Every pregnant individual has the fundamental right to choose to have an abortion, a right that is secured by the California Constitution.(b) Recent litigation has raised uncertainty about the continued availability nationwide of mifepristone, a drug that has been clinically proven to be part of a safe and effective means of providing medication abortion.(c) The continued attacks on reproductive freedom across the country require immediate action to protect the right to abortion access, including access to medication abortion, in California.(d) It is the intent of the Legislature to ensure continued access in California to critical abortion medication that has been proven safe and effective for two decades for individuals seeking abortion care.
SECTION 1. The Legislature finds and declares all of the following:(a) It is the longstanding public policy of this state to promote access to reproductive health care, including abortion care, without unnecessary burdens or restrictions on patients or providers. Every pregnant individual has the fundamental right to choose to have an abortion, a right that is secured by the California Constitution.(b) Recent litigation has raised uncertainty about the continued availability nationwide of mifepristone, a drug that has been clinically proven to be part of a safe and effective means of providing medication abortion.(c) The continued attacks on reproductive freedom across the country require immediate action to protect the right to abortion access, including access to medication abortion, in California.(d) It is the intent of the Legislature to ensure continued access in California to critical abortion medication that has been proven safe and effective for two decades for individuals seeking abortion care.
SECTION 1. The Legislature finds and declares all of the following:
### SECTION 1.
(a) It is the longstanding public policy of this state to promote access to reproductive health care, including abortion care, without unnecessary burdens or restrictions on patients or providers. Every pregnant individual has the fundamental right to choose to have an abortion, a right that is secured by the California Constitution.
(b) Recent litigation has raised uncertainty about the continued availability nationwide of mifepristone, a drug that has been clinically proven to be part of a safe and effective means of providing medication abortion.
(c) The continued attacks on reproductive freedom across the country require immediate action to protect the right to abortion access, including access to medication abortion, in California.
(d) It is the intent of the Legislature to ensure continued access in California to critical abortion medication that has been proven safe and effective for two decades for individuals seeking abortion care.
SEC. 2. Section 123467.4 is added to the Health and Safety Code, to read:123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.
SEC. 2. Section 123467.4 is added to the Health and Safety Code, to read:
### SEC. 2.
123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.
123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.
123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.
123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.
123467.4. (a) Notwithstanding any other law, a person, in exercising their individual rights under this article and Section 1.1 of Article I of the California Constitution, shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights under this article and the California Constitution, for using, receiving, possessing, or storing brand or generic mifepristone or any drug used for medication abortion.
(b) A person who aids or assists a pregnant person in exercising their rights under this article and the California Constitution shall not be subject to civil or criminal liability or penalty, or otherwise deprived of their rights, based solely on their actions to aid or assist a pregnant person in accessing brand or generic mifepristone or any drug used for medication abortion, in accordance with subdivision (a).
(c) The actions described in subdivisions (a) and (b) are lawful under the laws of California.
SECTION 1.SEC. 3. Section 127698 is added to the Health and Safety Code, to read:127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
SECTION 1.SEC. 3. Section 127698 is added to the Health and Safety Code, to read:
### SECTION 1.SEC. 3.
127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.
127698. (a) It is the intent of the Legislature to protect reproductive health access upon a decision in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, et al., U.S. Food and Drug Administration, et al. v. Alliance for Hippocratic Medicine, et al., related litigation, or other change under federal law. access.
(b) CHHSA or its departments may enter into partnerships resulting in the production, procurement, or distribution of mifepristone.
(c) In the event of a change in the approval status of mifepristone by the United States Food and Drug Administration, or a change in conditions for use or in the accessibility of mifepristone, CHHSA or its departments may develop a process to allow continued access to mifepristone, such as clinical trials or approval for use through the State Department of Public Health.